About this trial
This clinical trial is looking at a new treatment for women with recurrent ovarian cancer. The goal is to see how safe it is to use specially modified immune cells called T cells that are designed to target a specific receptor involved in cancer. This is the first study of its kind in people, and it will help researchers learn more about this new approach to treatment.
This is a Phase 1 trial, which means it is focused on understanding safety and finding the right dose of the treatment. The trial is regulated by the FDA and aims to include about 10 participants.
Who can join
Women aged 18 and older can join if they have certain types of recurrent ovarian cancer. They should have already tried at least two chemotherapy treatments and be considered unlikely to benefit from standard therapies. Participants also need to agree to some tests and may need to undergo a minor surgical procedure. The trial team will confirm eligibility for each interested participant.
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will receive infusions of modified T cells in different groups. Some will get the treatment through the abdomen (intraperitoneal), while others will receive it in the vein (intravenous). There are several dose levels, starting from lower amounts to higher amounts of the modified T cells. Everyone will receive the treatment, but they will be grouped based on how much they get.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
Moffitt Cancer Center
Tampa, Florida